Diabetes Autoimune Latente do adulto: uma forma incomum de diabetes mellitus
DOI:
https://doi.org/10.34119/bjhrv7n4-393Keywords:
Diabetes Mellitus, Diabetes do tipo 1.5, inibidores da Dipeptidil Peptidase IVAbstract
O diabetes automune latente do aduto (LADA) é um tipo incomum de diabetes. Assim como o diabetes tipo 1 (DM1) sua fisiopatologia se baseia em um processo autoimune, que resulta na destruição das células beta pancreáticas, com consequente insulinopenia. Entretanto, os pacientes com LADA apresentam varias características que os diferenciam dos pacientes com DM1. Dessa forma, ainda não existe um consenso a respeito da real definição da LADA, bem como de seus critérios diagnósticos e de seu manejo. Assim foi realizada uma revisão de literatura, com foco nos principais aspectos da doença, incluindo fisiopatologia, classificação, diagnósticos e manejo. A partir dos resultados, foi possível perceber que mesmo tendo uma fisiopatologia similar com a do DM1, os pacientes com LADA tendem a ter catacteristicas similiares aos daqueles com diabetes tipo 2 (DM2). Além disso, o manejo da LADA ainda é controverso, e difere tanto do manejo de DM1 quanto de DM2.
References
American Diabetes Association. “Diagnosis and classification of diabetes mellitus.” Diabetes care vol. 34 Suppl 1,Suppl 1 (2011): S62-9. doi:10.2337/dc11-S062
American Diabetes Association. “4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2020.” Diabetes care vol. 43,Suppl 1 (2020): S37-S47. doi:10.2337/dc20-S004
Bommer, Christian et al. “Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030.” Diabetes care vol. 41,5 (2018): 963-970. doi:10.2337/dc17-1962.
Buzzetti, Raffaella et al. “Adult-onset autoimmune diabetes: current knowledge and implications for management.” Nature reviews. Endocrinology vol. 13,11 (2017): 674-686. doi:10.1038/nrendo.2017.99
Buzzetti, Raffaella et al. “Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.” Diabetes vol. 69,10 (2020): 2037-2047. doi:10.2337/dbi20-0017
Buzzetti, R et al. “Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).” Diabetes/metabolism research and reviews vol. 32,3 (2016): 289-96. doi:10.1002/dmrr.2717
Carlsson, Sofia. “Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes.” Frontiers in physiology vol. 10 320. 26 Mar. 2019, doi:10.3389/fphys.2019.00320
Cheng, Bi-Wen et al. “Autoantibodies against islet cell antigens in children with type 1 diabetes mellitus.” Oncotarget vol. 9,23 16275-16283. 19 Feb. 2018, doi:10.18632/oncotarget.24527
Guglielmi, Chiara et al. “Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy.” Diabetes/metabolism research and reviews vol. 28 Suppl 2 (2012): 40-6. doi:10.1002/dmrr.2345
Liu, Lingjiao et al. “Latent autoimmune diabetes in adults with low-titer GAD antibodies: similar disease progression with type 2 diabetes: a nationwide, multicenter prospective study (LADA China Study 3).” Diabetes care vol. 38,1 (2015): 16-21. doi:10.2337/dc14-1770
Maraschin, Jorge de Faria et al. “Influence of age at diagnosis and duration of diabetes on the positivity of glutamic acid decarboxylase antibody in South-Brazilian type 1 diabetes mellitus.” Annals of clinical biochemistry vol. 50,Pt 3 (2013): 262-6. doi:10.1177/0004563212474560
Mollo, Angels et al. “Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain.” Diabetes/metabolism research and reviews vol. 29,6 (2013): 446-51. doi:10.1002/dmrr.2411
Palmer, Jerry P et al. “Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age?.” Diabetes vol. 54 Suppl 2 (2005): S62-7. doi:10.2337/diabetes.54.suppl_2.s62
Pan, Niansi et al. “Latent Autoimmune Diabetes in Adults and Metabolic Syndrome-A Mini Review.” Frontiers in endocrinology vol. 13 913373. 28 Jun. 2022, doi:10.3389/fendo.2022.913373
Paul, Shalini et al. “Molecular complexities underlying the vascular complications of diabetes mellitus - A comprehensive review.” Journal of diabetes and its complications vol. 34,8 (2020): 107613. doi:10.1016/j.jdiacomp.2020.107613
Rodacki M, Teles M, Gabbay M, Montenegro R, Bertoluci M, Rodrigo Lamounier. Classificação do diabetes. Diretriz Oficial da Sociedade Brasileira de Diabetes (2023). DOI: 10.29327/557753.2022-1, ISBN: 978-85-5722-906-8.
Yang, Lin et al. “Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial.” The Journal of clinical endocrinology and metabolism vol. 106,4 (2021): e1529-e1541. doi:10.1210/clinem/dgab026
Zhao, Yunjuan et al. “Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.” The Journal of clinical endocrinology and metabolism vol. 99,5 (2014): E876-80. doi:10.1210/jc.2013-3633
